An Epstein-Barr Virus-Associated Leukemic Lymphoma in a Patient Treated with Rabbit Antithymocyte Globulin and Cyclosporine for Hepatitis-Associated Aplastic Anemia

Lymphoproliferative disorders (LPDs) are generally caused by uncontrolled B-cell proliferation induced by the Epstein-Barr virus (EBV) in the setting of impaired EBV-specific T-cell immunity, particularly when there is pharmacological immunosuppression including antithymocyte globulin. We herein present an unusual case of EBV associated with LPD (EBV-LPD) in which LPD occurred 3 weeks after the use of rabbit antithymocyte globulin administered for severe hepatitis-associated aplastic anemia; the patient died of fulminant leukemic lymphoma 5 days after the onset. We also review the pertinent literature on EBV-LPD after immunosuppressive therapy and document the efficacy of EBV viral load monitoring and the need for preemptive therapy.

[1]  N. Young,et al.  Current concepts in the pathophysiology and treatment of aplastic anemia. , 2013, Hematology. American Society of Hematology. Education Program.

[2]  Y. Zu,et al.  Epstein–Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy , 2011, Medical oncology.

[3]  Tsutomu Yoshida,et al.  Lymphoproliferative Disorders after Immunosuppressive Therapy for Aplastic Anemia: A Case Report and Literature Review , 2009, Acta Haematologica.

[4]  J. Janssen,et al.  Monitoring of EBV reactivation is justified in patients with aplastic anemia treated with rabbit ATG as a second course of immunosuppression. , 2008, Blood.

[5]  H. Haario,et al.  Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  H. Mizoguchi,et al.  Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. , 2007, Blood.

[7]  S. Fischer,et al.  Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. , 2006, Blood.

[8]  R. Fanin,et al.  Epstein‐Barr virus reactivation in a patient treated with anti‐thymocyte globulin for severe aplastic anemia , 2006, American journal of hematology.

[9]  M. Caligiuri,et al.  IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice. , 2005, Blood.

[10]  A. Bacigalupo.  Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects , 2005, Bone Marrow Transplantation.

[11]  R. Krance,et al.  Prompt versus preemptive intervention for EBV lymphoproliferative disease. , 2004, Blood.

[12]  B. van der Holt,et al.  Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. , 2002, Blood.

[13]  F. Behm,et al.  Lactic acidosis: A metabolic complication of hematologic malignancies , 2001, Cancer.

[14]  B. van der Holt,et al.  Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT. , 2001, Blood.

[15]  N. Ogawa,et al.  T-Cell Type Acute Lymphoblastic Leukemia Following Cyclosporin A Therapy for Aplastic Anemia , 2001, International journal of hematology.

[16]  M. Takeuchi,et al.  Philadelphia chromosome positive acute lymphocytic leukemia arising from aplastic anemia , 2000, American journal of hematology.

[17]  R. Saxena,et al.  Severe aplastic anemia evolving into T cell acute lymphoblastic leukemia , 1999, European journal of haematology.

[18]  J. Woodroof,et al.  First report of a B cell lymphoproliferative disorder arising in a patient treated with immune suppressants for severe aplastic anemia , 1996, American journal of hematology.

[19]  Y. Kodera,et al.  Circulating activated suppressor T lymphocytes in hepatitis‐associated aplastic anaemia , 1989, British journal of haematology.